Search

Your search keyword '"Brice, Pauline"' showing total 1,034 results
Start Over Author "Brice, Pauline"
1,034 results on '"Brice, Pauline"'

102. Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

Author

Bachy, Emmanuel, primary, Seymour, John F., additional, Feugier, Pierre, additional, Offner, Fritz, additional, López-Guillermo, Armando, additional, Belada, David, additional, Xerri, Luc, additional, Catalano, John V., additional, Brice, Pauline, additional, Lemonnier, François, additional, Martin, Alejandro, additional, Casasnovas, Olivier, additional, Pedersen, Lars M., additional, Dorvaux, Véronique, additional, Simpson, David, additional, Leppa, Sirpa, additional, Gabarre, Jean, additional, da Silva, Maria G., additional, Glaisner, Sylvie, additional, Ysebaert, Loic, additional, Vekhoff, Anne, additional, Intragumtornchai, Tanin, additional, Le Gouill, Steven, additional, Lister, Andrew, additional, Estell, Jane A., additional, Milone, Gustavo, additional, Sonet, Anne, additional, Farhi, Jonathan, additional, Zeuner, Harald, additional, Tilly, Hervé, additional, and Salles, Gilles, additional

Published
2019
Full Text
View/download PDF

104. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Author

Morschhauser, Franck, Fowler, Nathan H, Feugier, Pierre, Bouabdallah, Reda, Tilly, Hervé, Palomba, M Lia, Fruchart, Christophe, Libby, Edward N, Casasnovas, Rene-Olivier, Flinn, Ian W, Haioun, Corinne, Maisonneuve, Hervé, Ysebaert, Loic, Bartlett, Nancy L, Bouabdallah, Kamal, Brice, Pauline, Ribrag, Vincent, Daguindau, Nicolas, Le Gouill, Steven, Pica, Gian M, Martin Garcia-Sancho, Alejandro, López-Guillermo, Armando, Larouche, Jean-François, Ando, Kiyoshi, Gomes da Silva, Maria, André, Marc, Zachée, Pierre, Sehn, Laurie H, Tobinai, Kensei, Cartron, Guillaume, Liu, David, Wang, Jianming, Xerri, Luc, Salles, Gilles A, Abdel-Samad N, Abdo-Matkiwsky M, Abraham J, Abrisqueta P, Anglaret B, Barnes JA, Benbrahim O, Bierman PJ, Bonnet C, Brault P, Bron D, Brooks BJ Jr, Byeff P, Casanova M, Cheung M, Choudhary Y, Comeau T, Cooper B, Couban S, Cox MC, Crump M, Deau Fischer B, Deconinck E, Deeren D, de la Cruz Vicente F, Delarue R, Del Campo R, Delmer A, Delwail V, Duggan PR, Eisenmann DJRM, El Yamani A, Eradat HA, Fabbro M, Farber C, Fisher DC, Fleischman RA, Fleck E, Fornecker LM, Foussard C, Gabarre J, Gaffar YA, Gallardo D, Ghazal H, Giagounidis A, Gill K, Glaisner S, Gonzalez H, Greenberg RH, Goubran Messiha H, Goy A, Gressin R, Gyan E, Hart LL, Hatake K, Hiddemann W, Hodossy B, Horkheimer I, Hoyer RJ, Huebel K, Ishikawa T, Izutsu K, Jardel H, Jhangiani HS, Johnson N, Joly B, Jourdan E, Kargar Samani K, Kato K, Kiguchi T, Kobayashi T, Kohser F, Koike M, Kouroukis C T, Laferriere N, Lamy de la Chapelle T, Landau DA, Lawler WE, Lemieux B, Levitan DA, Longree L, Lopez J, Mace J, Maerevoet M, Maigre M, Marjanovic Z, Michel J, Mounier C, Muntanola A, Ngirabacu MC, Nicolas-Virelizier E, Novelli S, Offner F, Palomera L, Pandit LH, Panwalkar A, Pierre P, Pignon JM, Pinto A, Plöger C, Pranger D, Quick DP, Reyes EA, Robin V, Robu D, Rodriguez Salazar MJ, Rosen PJ, Rosenbluth J, Sadot-Lebouvier S, Sangha R, Segota Z, Shapira I, Shtivelband M, Simon M, Soekler M, Soubeyran P, Taper J, Tereblo HR, Terol MJ, The AS, Ueda Y, van den Neste E, van Eygen K, van Hoof A, Vanstraelen G, Verner E, Warburton P, Yamamoto G, Yokoyama H, Zerazhi H, Zinzani PL., Morschhauser, Franck, Fowler, Nathan H, Feugier, Pierre, Bouabdallah, Reda, Tilly, Hervé, Palomba, M Lia, Fruchart, Christophe, Libby, Edward N, Casasnovas, Rene-Olivier, Flinn, Ian W, Haioun, Corinne, Maisonneuve, Hervé, Ysebaert, Loic, Bartlett, Nancy L, Bouabdallah, Kamal, Brice, Pauline, Ribrag, Vincent, Daguindau, Nicola, Le Gouill, Steven, Pica, Gian M, Martin Garcia-Sancho, Alejandro, López-Guillermo, Armando, Larouche, Jean-Françoi, Ando, Kiyoshi, Gomes da Silva, Maria, André, Marc, Zachée, Pierre, Sehn, Laurie H, Tobinai, Kensei, Cartron, Guillaume, Liu, David, Wang, Jianming, Xerri, Luc, Salles, Gilles A, Abdel-Samad N, Abdo-Matkiwsky M, Abraham J, Abrisqueta P, Anglaret B, Barnes JA, Benbrahim O, Bierman PJ, Bonnet C, Brault P, Bron D, Brooks BJ Jr, Byeff P, Casanova M, Cheung M, Choudhary Y, Comeau T, Cooper B, Couban S, Cox MC, Crump M, Deau Fischer B, Deconinck E, Deeren D, de la Cruz Vicente F, Delarue R, Del Campo R, Delmer A, Delwail V, Duggan PR, Eisenmann DJRM, El Yamani A, Eradat HA, Fabbro M, Farber C, Fisher DC, Fleischman RA, Fleck E, Fornecker LM, Foussard C, Gabarre J, Gaffar YA, Gallardo D, Ghazal H, Giagounidis A, Gill K, Glaisner S, Gonzalez H, Greenberg RH, Goubran Messiha H, Goy A, Gressin R, Gyan E, Hart LL, Hatake K, Hiddemann W, Hodossy B, Horkheimer I, Hoyer RJ, Huebel K, Ishikawa T, Izutsu K, Jardel H, Jhangiani HS, Johnson N, Joly B, Jourdan E, Kargar Samani K, Kato K, Kiguchi T, Kobayashi T, Kohser F, Koike M, Kouroukis C T, Laferriere N, Lamy de la Chapelle T, Landau DA, Lawler WE, Lemieux B, Levitan DA, Longree L, Lopez J, Mace J, Maerevoet M, Maigre M, Marjanovic Z, Michel J, Mounier C, Muntanola A, Ngirabacu MC, Nicolas-Virelizier E, Novelli S, Offner F, Palomera L, Pandit LH, Panwalkar A, Pierre P, Pignon JM, Pinto A, Plöger C, Pranger D, Quick DP, Reyes EA, Robin V, Robu D, Rodriguez Salazar MJ, Rosen PJ, Rosenbluth J, Sadot-Lebouvier S, Sangha R, Segota Z, Shapira I, Shtivelband M, Simon M, Soekler M, Soubeyran P, Taper J, Tereblo HR, Terol MJ, The AS, Ueda Y, van den Neste E, van Eygen K, van Hoof A, Vanstraelen G, Verner E, Warburton P, Yamamoto G, Yokoyama H, Zerazhi H, Zinzani PL., Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Department of Lymphoma and Myeloma [Houston, TX, USA], The University of Texas M.D. Anderson Cancer Center [Houston], Service d'Hématologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département d’Hématologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Institut d'Hématologie de Basse-Normandie (IHBN), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-UNICANCER, Service d'Hématologie Clinique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Unité des hémopathies lymphoïdes [CHU Henri Mondor], CHU Henri Mondor, Service d’Onco-Hématologie [La Roche sur Yon], Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service d'hématologie [CHU Bordeaux], CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Service d'onco-hématologie [AP-HP Hôpital Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département d'hématologie [Gustave Roussy], Institut Gustave Roussy (IGR), Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma (CRCINA-ÉQUIPE 10), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Service d'Hématologie Clinique [Hôpital Hôtel Dieu, Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes)-Hôpital Hôtel Dieu, Service Hématologie [CH Métropole Savoie, Chambery], Centre Hospitalier Métropole Savoie [Chambéry], Département d'Hématologie [CHU de Montpellier], Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Département d'Hématologie [CH Lyon-Sud], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), RELEVANCE Trial Investigators : Abdel-Samad N, Abdo-Matkiwsky M, Abraham J, Abrisqueta P, Anglaret B, Barnes JA, Benbrahim O, Bierman PJ, Bonnet C, Brault P, Bron D, Brooks BJ Jr, Byeff P, Casanova M, Cheung M, Choudhary Y, Comeau T, Cooper B, Couban S, Cox MC, Crump M, Deau Fischer B, Deconinck E, Deeren D, de la Cruz Vicente F, Delarue R, Del Campo R, Delmer A, Delwail V, Duggan PR, Eisenmann DJRM, El Yamani A, Eradat HA, Fabbro M, Farber C, Fisher DC, Fleischman RA, Fleck E, Fornecker LM, Foussard C, Gabarre J, Gaffar YA, Gallardo D, Ghazal H, Giagounidis A, Gill K, Glaisner S, Gonzalez H, Greenberg RH, Goubran Messiha H, Goy A, Gressin R, Gyan E, Hart LL, Hatake K, Hiddemann W, Hodossy B, Horkheimer I, Hoyer RJ, Huebel K, Ishikawa T, Izutsu K, Jardel H, Jhangiani HS, Johnson N, Joly B, Jourdan E, Kargar Samani K, Kato K, Kiguchi T, Kobayashi T, Kohser F, Koike M, Kouroukis C T, Laferriere N, Lamy de la Chapelle T, Landau DA, Lawler WE, Lemieux B, Levitan DA, Longree L, Lopez J, Mace J, Maerevoet M, Maigre M, Marjanovic Z, Michel J, Mounier C, Muntanola A, Ngirabacu MC, Nicolas-Virelizier E, Novelli S, Offner F, Palomera L, Pandit LH, Panwalkar A, Pierre P, Pignon JM, Pinto A, Plöger C, Pranger D, Quick DP, Reyes EA, Robin V, Robu D, Rodriguez Salazar MJ, Rosen PJ, Rosenbluth J, Sadot-Lebouvier S, Sangha R, Segota Z, Shapira I, Shtivelband M, Simon M, Soekler M, Soubeyran P, Taper J, Tereblo HR, Terol MJ, The AS, Ueda Y, van den Neste E, van Eygen K, van Hoof A, Vanstraelen G, Verner E, Warburton P, Yamamoto G, Yokoyama H, Zerazhi H, Zinzani PL., Bernardo, Elizabeth, CHU Henri Mondor [Créteil], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille, Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Centre Hospitalier Départemental Vendée, Service d'Hématologie [IUCT Toulouse], Université Fédérale Toulouse Midi-Pyrénées-Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), and Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)

Subjects
Adult, Male, medicine.medical_specialty, Neutropenia, Intention to Treat Analysi, Follicular lymphoma, [SDV.CAN]Life Sciences [q-bio]/Cancer, Gastroenterology, Skin Diseases, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Maintenance therapy, immune system diseases, Internal medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Survival rate, Lenalidomide, Lymphoma, Follicular, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocol, business.industry, Skin Disease, General Medicine, Middle Aged, medicine.disease, 3. Good health, Intention to Treat Analysis, Thalidomide, Survival Rate, Regimen, 030220 oncology & carcinogenesis, Rituximab, Female, business, Febrile neutropenia, 030215 immunology, medicine.drug, Human
Abstract

International audience; BACKGROUND:Rituximab plus chemotherapy has been shown to be effective in patients with advanced-stage, previously untreated follicular lymphoma; nevertheless, most patients will have a relapse. Combination immunotherapy with lenalidomide and rituximab is an immunomodulatory regimen that has shown promising activity in patients with indolent B-cell non-Hodgkin's lymphoma.METHODS:We conducted this multicenter, international, phase 3 superiority trial to evaluate rituximab plus lenalidomide, as compared with rituximab plus chemotherapy, in patients with previously untreated follicular lymphoma. Patients were randomly assigned to receive one of the two regimens, followed by maintenance monotherapy with rituximab. Treatment with rituximab plus lenalidomide consisted of 18 cycles of the two drugs, followed by rituximab maintenance therapy every 8 weeks for 12 cycles (six additional doses). Treatment with rituximab plus chemotherapy consisted of the investigator's choice of one of three rituximab-based regimens, followed by maintenance monotherapy with rituximab every 8 weeks for 12 cycles. The primary end points were complete response (confirmed or unconfirmed) at 120 weeks and progression-free survival.RESULTS:A total of 1030 patients were randomly assigned to receive rituximab plus lenalidomide (513 patients) or rituximab plus chemotherapy (517 patients). The rate of confirmed or unconfirmed complete response at 120 weeks was similar in the two groups: 48% (95% confidence interval [CI], 44 to 53) in the rituximab-lenalidomide group and 53% (95% CI, 49 to 57) in the rituximab-chemotherapy group (P=0.13). The interim 3-year rate of progression-free survival was 77% (95% CI, 72 to 80) and 78% (95% CI, 74 to 82), respectively. A higher percentage of patients in the rituximab-chemotherapy group had grade 3 or 4 neutropenia (32% vs. 50%) and febrile neutropenia of any grade (2% vs. 7%), and a higher percentage of patients in the rituximab-lenalidomide group had grade 3 or 4 cutaneous reactions (7% vs. 1%).CONCLUSIONS:Among patients with previously untreated follicular lymphoma, efficacy results were similar with rituximab plus lenalidomide and rituximab plus chemotherapy (with both regimens followed by rituximab maintenance therapy). The safety profile differed in the two groups. (Funded by Celgene; RELEVANCE ClinicalTrials.gov numbers, NCT01476787 and NCT01650701 , and EudraCT number, 2011-002792-42 .).

Published
2018

107. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucemies et Autres Maladies du Sang (GOELAMS)

Author

Morschhauser, Franck, Mounier, Nicolas, Sebban, Catherine, Brice, Pauline, Solal-Celigny, Phillippe, Tilly, Herve, Feugier, Pierre, Ferme, Christophe, Copin, Marie Christine, and Lamy, Thierry

Subjects
Non-Hodgkin's lymphomas -- Care and treatment, Non-Hodgkin's lymphomas -- Research, Fludarabine -- Dosage and administration, Fludarabine -- Research, Chemotherapy, Combination -- Safety and security measures, Chemotherapy, Combination -- Research, Health
Published
2010

111. PET-guided, BEACOPP therapy in advanced Hodgkin lymphoma - Authors' reply

Author

Casasnovas, René-Olivier, Bouabdallah, Reda, Brice, Pauline, Lazarovici, Julien, Ghesquieres, Hervé, Stamatoullas, Aspasia, Berriolo-Riedinger, Alina, Fornecker, Luc-Matthieu, André, Marc, Meignan, Michel, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, and UCL - (MGD) Service d'hématologie

Published
2019

114. High-dose therapy and autologous stem-cell transplantation can improve event-free survival for indolent lymphoma: a study using patients as their own controls

Author

Vignot, Stephane, Mounier, Nicolas, Larghero, Jerome, Brice, Pauline, Quero, Laurent, de Bazelaire, Cedric, Ertault, Marjan, Briere, Josette, Madelaine, Isabelle, and Gisselbrecht, Christian

Subjects
Lymphomas -- Care and treatment, Lymphomas -- Patient outcomes, Lymphomas -- Research, Chemotherapy -- Dosage and administration, Chemotherapy -- Research, Stem cells -- Transplantation, Stem cells -- Patient outcomes, Stem cells -- Research, Cancer -- Chemotherapy, Cancer -- Dosage and administration, Cancer -- Research, Health
Published
2007

115. Follicular Lymphoma International Prognostic Index

Author

Solal-Céligny, Philippe, Roy, Pascal, Colombat, Philippe, White, Josephine, Armitage, Jim O., Arranz-Saez, Reyes, Au, Wing Y., Bellei, Monica, Brice, Pauline, Caballero, Dolores, Coiffier, Bertrand, Conde-Garcia, Eulogio, Doyen, Chantal, Federico, Massimo, Fisher, Richard I., Garcia-Conde, Javier F., Guglielmi, Cesare, Hagenbeek, Anton, Haïoun, Corinne, LeBlanc, Michael, Lister, Andrew T., Lopez-Guillermo, Armando, McLaughlin, Peter, Milpied, Noël, Morel, Pierre, Mounier, Nicolas, Proctor, Stephen J., Rohatiner, Ama, Smith, Paul, Soubeyran, Pierre, Tilly, Hervé, Vitolo, Umberto, Zinzani, Pier-Luigi, Zucca, Emanuele, and Montserrat, Emili

Published
2004
Full Text
View/download PDF

122. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma

Author

Solal-Celigny, Philippe, Lepage, Eric, Brousse, Nicole, Reyes, Felix, Haioun, Corinne, Leporrier, Michel, Peuchmaur, Michel, Bosly, Andre, Parlier, Yolaine, Brice, Pauline, Coiffier, Bertrand, and Gisselbrecht, Christian

Subjects
Non-Hodgkin's lymphomas, Interferon alpha -- Health aspects
Abstract

Interferon alfa combined with chemotherapy may enhance the therapy response rate in patients with advanced non-Hodgkin's lymphomas. Non-Hodgkin's lymphomas are malignant tumors of the lymph nodes. Interferon alpha is a component of the immune response with antiviral.Researchers assigned 119 patients to chemotherapy and 123 to chemotherapy plus interferon alpha. Eighty-two chemotherapy patients and 104 chemotherapy plus interferon alpha patients responded to therapy by the end of the trial. By that time, 39 patients in the chemotherapy group and 26 in the interferon alpha group had died. Patients treated with chemotherapy alone had average event-free survival rates of 19 months. Patients who also took interferon alpha averaged 34 months without incident. At three years, 89% of the interferon alpha patients survived compared to 69% of the chemotherapy patients. Interferon alpha therapy was stopped in 13 patients and decreased in 19 others due to adverse effects.

Published
1993

125. Advanced Hodgkin disease with large mediastinal involvement can be treated with eight cycles of chemotherapy alone after a major response to six cycles of chemotherapy: a study of 82 patients from the Groupes d'Etudes des Lyphomes de l'Adulte H89 trial

Author

Brice, Pauline, Colin, Philippe, Berger, Francoise, Kerviler, Eric de, Divine, Marine, Bouaffia, Fadellah, Kerneis, Yves, Blanc, Michel, Lepage, Eric, and Ferme, Christophe

Subjects
Hodgkin's disease, Thoracic cancer, Health
Published
2001

128. Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study

Author

Gyan, Emmanuel, Sonet, Anne, Brice, Pauline, Anglaret, Bruno, Laribi, Kamel, Fruchart, Christophe, Tilly, Hervé, Araujo, Carla, Soubeyran, Pierre, Gonzalez, Hugo, Morineau, Nadine, Nicolas-Virelizier, Emmanuelle, Ghesquières, Hervé, Salles, Bruno, Bouabdallah, Réda, Orfeuvre, Hubert, Fahri, Jonathan, Couturier, Olivier, Xerri, Luc, Feugier, Pierre, Lymphoma Study Association (LYSA), Service d'hématologie, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université Catholique de Louvain = Catholic University of Louvain (UCL), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier de Valence (Unité d'Hématologie), Centre hospitalier de Valence, Centre Hospitalier Le Mans (CH Le Mans), Institut d'Hématologie de Basse-Normandie (IHBN), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER, Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hématologie (CH de la Côte Basque), Le CHCB, Centre Hospitalier de la Côte Basque, Plateforme de génétique moléculaire des cancers d'Aquitaine, Institut Bergonié [Bordeaux], UNICANCER-UNICANCER, Centre Catherine-de-Sienne [Nantes] (CCS), Centre Léon Bérard [Lyon], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre Hospitalier de Bourg en Bresse, Service des maladies du sang [Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Design and Application of Innovative Local Treatments in Glioblastoma (CRCINA-ÉQUIPE 17), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Service d'Hématologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Service d'hématologie

Subjects
Bendamustine, Male, medicine.medical_specialty, Efficacy, [SDV]Life Sciences [q-bio], efficacy, Follicular lymphoma, Phases of clinical research, Gastroenterology, Maintenance Chemotherapy, 03 medical and health sciences, 0302 clinical medicine, International Prognostic Index, rituximab, Maintenance therapy, follicular lymphoma, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Bendamustine Hydrochloride, Humans, bendamustine, Lymphoma, Follicular, Aged, Aged, 80 and over, tolerance, business.industry, Remission Induction, Hematology, Middle Aged, medicine.disease, Survival Analysis, 3. Good health, Lymphoma, Tumor Burden, Regimen, Treatment Outcome, 030220 oncology & carcinogenesis, Rituximab, Female, business, Tolerance, 030215 immunology, medicine.drug
Abstract

International audience; The treatment of low-tumour burden follicular lymphoma (LTBFL) remains a challenge. Rituximab-based strategies may be improved by adding chemotherapy. This Lymphoma Study Association multicentre phase II study assessed rituximab and bendamustine in 63 patients with untreated LTBFL who were aged over 60years old and had a follicular lymphoma International Prognostic Index (FLIPI) score ≥2. Induction comprised 4 weekly cycles of rituximab 375mg/m intravenously combined with 2 cycles of bendamustine 90mg/m days 1-2 with a 28-day interval, followed by twelve cycles of 375mg/m rituximab maintenance therapy every 8weeks. The primary endpoint was complete response (CR)/unconfirmed CR (CRu), at 12weeks. Median age was 67·4years and median FLIPI was 3. Ultimately, 18 patients (29%) had high tumour burden according to Groupe d'Etude des Lymphomes Folliculaires criteria. The 12-week CR/CRu rate was 54·0% and the overall response rate was 93·7%. Surprisingly, 3 patients died during maintenance (2 sepsis, 1 neoplasm). Progression-free survival was 85·4% at 24months. In LTBFL patients with FLIPI ≥2, two cycles of rituximab and bendamustine result in a CR rate of 54·0%. However, the treatment-related deaths observed do not allow this regimen to be recommended for LTBFL patients aged over 60years. EudraCT: 2010-020757-14; ClinicalTrials.gov: NCT01313611.

Published
2018

129. Nivolumab Combined with Brentuximab Vedotin (BV) for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (R/R PMBL): Efficacy and Safety Results from the Phase 2 CheckMate 436 Study

Author

Zinzani, Pier Luigi, primary, Santoro, Armando, additional, Gritti, Guiseppe, additional, Brice, Pauline, additional, Barr, Paul M., additional, Kuruvilla, John, additional, Cunningham, David, additional, Kline, Justin, additional, Johnson, Nathalie A., additional, Mehta-Shah, Neha A., additional, Manley, Thomas, additional, Francis, Stephen, additional, Sharma, Manish, additional, and Moskowitz, Alison J., additional

Published
2019
Full Text
View/download PDF

130. Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation

Author

Manson, Guillaume, primary, Mear, Jean-Baptiste, additional, Herbaux, Charles, additional, Schiano, Jean-Marc, additional, Casasnovas, Olivier, additional, Stamatoullas, Aspasia, additional, Deau, Bénédicte, additional, Schmitt, Anna, additional, Garnier, Georges, additional, Regny, Caroline, additional, Bouabdallah, Krimo, additional, Moles-Moreau, Marie-Pierre, additional, Ghesquieres, Hervé, additional, Tempescul, Adrian, additional, Dulery, Remy, additional, Nicolas-Virelizier, Emmanuelle, additional, Delmer, Alain, additional, Borel, Cecile, additional, Chauchet, Adrien, additional, Damotte, Diane, additional, Dercle, Laurent, additional, Brice, Pauline, additional, and Houot, Roch, additional

Published
2019
Full Text
View/download PDF

131. Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC

Author

Garciaz, Sylvain, primary, Loschi, Mickael, additional, De Masson, Adèle, additional, Biard, Lucie, additional, Mercier, Mélanie, additional, Tomowiak, Cécile, additional, Delage, Jeremy, additional, Labussiere-Wallet, Hélène, additional, Sibon, David, additional, Cassuto, Ophélie, additional, Borel, Cécile, additional, Cornillon, Jérome, additional, Nimubona, Stanislas, additional, Charbonnier, Amandine, additional, Brice, Pauline, additional, Socié, Gérard, additional, Bouabdallah, Reda, additional, de Latour, Régis Peffault, additional, and de Fontbrune, Flore Sicre, additional

Published
2019
Full Text
View/download PDF

132. Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma

Author

von Tresckow, Bastian, primary, Fanale, Michelle, additional, Ardeshna, Kirit M., additional, Chen, Robert, additional, Meissner, Julia, additional, Morschhauser, Franck, additional, Moskowitz, Craig, additional, Zinzani, Pier Luigi, additional, Giezek, Hilde, additional, Balakumaran, Arun, additional, Vo, Thao T., additional, Raut, Monika, additional, and Brice, Pauline, additional

Published
2019
Full Text
View/download PDF

134. Post-transplant outcome of ovarian tissue cryopreserved after chemotherapy in hematologic malignancies

Author

Poirot, Catherine, primary, Fortin, Anne, additional, Dhédin, Nathalie, additional, Brice, Pauline, additional, Socié, Gérard, additional, Lacorte, Jean-Marc, additional, Akakpo, Jean-Paul, additional, Genestie, Catherine, additional, Vernant, Jean-Paul, additional, Leblanc, Thierry, additional, Gabarre, Jean, additional, Delmer, Alain, additional, Badachi, Yasmina, additional, Drouineaud, Véronique, additional, Chalas, Céline, additional, Egels, Sophie, additional, Touraine, Philippe, additional, Dommergues, Marc, additional, Lebègue, Géraldine, additional, Wolf, Jean-Philippe, additional, Capron, Frédérique, additional, Lefebvre, Gilles, additional, and Boissel, Nicolas, additional

Published
2019
Full Text
View/download PDF

135. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study

Author

Casasnovas, René-Olivier, primary, Bouabdallah, Reda, additional, Brice, Pauline, additional, Lazarovici, Julien, additional, Ghesquieres, Hervé, additional, Stamatoullas, Aspasia, additional, Dupuis, Jehan, additional, Gac, Anne-Claire, additional, Gastinne, Thomas, additional, Joly, Bertrand, additional, Bouabdallah, Krimo, additional, Nicolas-Virelizier, Emmanuelle, additional, Feugier, Pierre, additional, Morschhauser, Franck, additional, Delarue, Richard, additional, Farhat, Hassan, additional, Quittet, Philippe, additional, Berriolo-Riedinger, Alina, additional, Tempescul, Adrian, additional, Edeline, Véronique, additional, Maisonneuve, Hervé, additional, Fornecker, Luc-Matthieu, additional, Lamy, Thierry, additional, Delmer, Alain, additional, Dartigues, Peggy, additional, Martin, Laurent, additional, André, Marc, additional, Mounier, Nicolas, additional, Traverse-Glehen, Alexandra, additional, and Meignan, Michel, additional

Published
2019
Full Text
View/download PDF

136. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Author

Horwitz, Steven, primary, O'Connor, Owen A, additional, Pro, Barbara, additional, Illidge, Tim, additional, Fanale, Michelle, additional, Advani, Ranjana, additional, Bartlett, Nancy L, additional, Christensen, Jacob Haaber, additional, Morschhauser, Franck, additional, Domingo-Domenech, Eva, additional, Rossi, Giuseppe, additional, Kim, Won Seog, additional, Feldman, Tatyana, additional, Lennard, Anne, additional, Belada, David, additional, Illés, Árpád, additional, Tobinai, Kensei, additional, Tsukasaki, Kunihiro, additional, Yeh, Su-Peng, additional, Shustov, Andrei, additional, Hüttmann, Andreas, additional, Savage, Kerry J, additional, Yuen, Sam, additional, Iyer, Swaminathan, additional, Zinzani, Pier Luigi, additional, Hua, Zhaowei, additional, Little, Meredith, additional, Rao, Shangbang, additional, Woolery, Joseph, additional, Manley, Thomas, additional, Trümper, Lorenz, additional, Aboulafia, David, additional, Alpdogan, Onder, additional, Ando, Kiyoshi, additional, Arcaini, Luca, additional, Baldini, Luca, additional, Bellam, Naresh, additional, Bartlett, Nancy, additional, Yehuda, Dina Ben, additional, Benedetti, Fabio, additional, Borchman, Peter, additional, Bordessoule, Dominique, additional, Brice, Pauline, additional, Briones, Javier, additional, Caballero, Dolores, additional, Carella, Angelo Michele, additional, Chang, Hung, additional, Cheong, June Weon, additional, Cho, Seok-Goo, additional, Choi, Ilseung, additional, Choquet, Sylvain, additional, Colita, Andrei, additional, Congui, Angela Giovanna, additional, D'amore, Francesco, additional, Dang, Nam, additional, Davison, Kelly, additional, de Guibert, Sophie, additional, Brown, Peter de Nully, additional, Delwail, Vincent, additional, Demeter, Judit, additional, di Raimondo, Francesco, additional, Do, Young Rok, additional, Domingo, Eva, additional, Douvas, Michael, additional, Dreyling, Martin, additional, Ernst, Thomas, additional, Fay, Keith, additional, Ferrero, Silvia Fernandez, additional, Flinn, Ian Winchester, additional, Forero-Torres, Andres, additional, Fox, Christopher, additional, Friedberg, Jonathan, additional, Fukuhara, Noriko, additional, Garcia-Marco, Jose, additional, Cruz, Jorge Gayoso, additional, Codina, Jose Gomez, additional, Gressin, Remy, additional, Grigg, Andrew, additional, Gurion, Ronit, additional, Haioun, Corinne, additional, Hajek, Roman, additional, Hanel, Mathias, additional, Hatake, Kiyohiko, additional, Hensen, Robert, additional, Horowitz, Netanel, additional, Horwitz, Steven, additional, Huttmann, Andreas, additional, Illes, Arpad, additional, Ishizawa, Kenichi, additional, Islas-Ohlmayer, Miguel, additional, Jacobsen, Eric, additional, Janakiram, Murali, additional, Jurczak, Wojciech, additional, Kaminski, Mark, additional, Kato, Koji, additional, Kirgner, Ilya, additional, Kuo, Ching-Yuan, additional, Lazaroiu, Mihaela Cornelia, additional, Du, Katell Le, additional, Lee, Jong-Seok, additional, LeGouill, Steven, additional, LaRosee, Paul, additional, Levi, Itai, additional, Link, Brian, additional, Maisonneuve, Herve, additional, Maruyama, Dai, additional, Mayer, Jiri, additional, McCarty, John, additional, McKay, Pam, additional, Minami, Yosuke, additional, Mocikova, Heidi, additional, Morra, Enrica, additional, Munoz, Javier, additional, Nagai, Hirokazu, additional, O'Connor, Owen, additional, Opat, Stephen, additional, Pettengell, Ruth, additional, Pezzutto, Antonio, additional, Pfreundschuh, Michael, additional, Pluta, Andrzej, additional, Porcu, PierLuigi, additional, Quach, Hang, additional, Rambaldi, Alessandro, additional, Renwick, William, additional, Reyes, Ruben, additional, Izquierdo, Antonia Rodriguez, additional, Ruan, Jia, additional, Rusconi, Chiara, additional, Salles, Gilles, additional, Santoro, Armando, additional, Sarriera, Jose, additional, Savage, Kerry, additional, Shibayama, Hirohiko, additional, Suh, Cheolwon, additional, Sureda, Anna, additional, Tanimoto, Mitsune, additional, Taniwaki, Masafumi, additional, Tilly, Herve, additional, Trneny, Marek, additional, Trumper, Lorenz, additional, Tsukamoto, Norifumi, additional, Vitolo, Umberto, additional, Walewski, Jan, additional, Weidmann, Eckhart, additional, Wilhelm, Martin, additional, Witzens-Harig, Mathias, additional, Yacoub, Abdulraheem, additional, Yamamoto, Kazuhito, additional, Yoon, Sung-Soo, additional, Yun, Hwan Jung, additional, and Zain, Jasmine, additional

Published
2019
Full Text
View/download PDF

139. Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the Lysa EORTC 20012 Randomized Protocol

Author

Canioni, Danielle, primary, Brice, Pauline, additional, Bologna, Serge, additional, Voillat, Laurent, additional, Gabarre, Jean, additional, Casasnovas, Olivier, additional, Devidas, Alain, additional, Coiffier, Bertrand, additional, Aoudjhane, Malek, additional, Audhuy, Bruno, additional, Andre, Marc, additional, Fortpied, Catherine, additional, Carde, Patrice, additional, Mounier, Nicolas, additional, and Briere, Josette, additional

Published
2018
Full Text
View/download PDF

141. Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Author

Zinzani, Pier Luigi, primary, Chen, Robert W., additional, Lee, Hun Ju, additional, Armand, Philippe, additional, Johnson, Nathalie A, additional, Brice, Pauline, additional, Radford, John, additional, Ribrag, Vincent, additional, Molin, Daniel, additional, Vassilakopoulos, Theodoros P., additional, Tomita, Akihiro, additional, Von Tresckow, Bastian, additional, Shipp, Margaret A., additional, Kim, Eunhee, additional, Nahar, Akash, additional, Balakumaran, Arun, additional, and Moskowitz, Craig H., additional

Published
2018
Full Text
View/download PDF

142. Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial

Author

Moskowitz, Alison J., primary, Santoro, Armando, additional, Gritti, Giuseppe, additional, Brice, Pauline, additional, Cunningham, David, additional, Barr, Paul, additional, Kline, Justin, additional, Kuruvilla, John, additional, Johnson, Nathalie A, additional, Mehta-Shah, Neha, additional, Manley, Thomas, additional, Sharma, Manish, additional, Francis, Stephen, additional, Cohen, Joseph, additional, and Zinzani, Pier Luigi, additional

Published
2018
Full Text
View/download PDF

143. Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study

Author

Hagenbeek, Anton, primary, Zijlstra, Josée M, additional, Plattel, Wouter J, additional, Morschhauser, Franck, additional, Lugtenburg, Petronella J, additional, Brice, Pauline, additional, Hutchings, Martin, additional, Gastinne, Thomas, additional, Liu, Roberto D, additional, Burggraaf, Coreline N, additional, Nijland, Marcel, additional, Tonino, Sanne H, additional, van Tinteren, Harm, additional, Lopez Yurda, Marta I, additional, and Kersten, Marie José, additional

Published
2018
Full Text
View/download PDF

144. Superiority of Allogenic Stem Cell Transplantation after Anti-PD1 Therapy over Anti-PD1 Monotherapy Alone in Relapse/Refractory Hodgkin Lymphoma: Real World Evidence from the French Early Access Program

Author

Manson, Guillaume, primary, Mear, Jean-Baptiste, additional, Herbaux, Charles, additional, Schiano de Collela, Jean Marc, additional, Casasnovas, Rene-Olivier, additional, Stamatoullas, Aspasia, additional, Deau-Fisher, Bénédicte, additional, Schmitt, Anna, additional, Garnier, Georges, additional, Molina, Lysiane, additional, Bouabdallah, Krimo, additional, Moles, Marie-Pierre, additional, Ghesquieres, Herv, additional, Tempescul, Adrian, additional, Dulery, Remy, additional, Nicolas-Virelizier, Emmanuelle, additional, Delmer, Alain Jacques, additional, Borel, Cecile, additional, Chauchet, Adrien, additional, Dercle, Laurent, additional, Brice, Pauline, additional, and Houot, Roch, additional

Published
2018
Full Text
View/download PDF

147. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Author

Chen, Robert Zinzani, Pier Luigi Fanale, Michelle A. Armand, Philippe Johnson, Nathalie A. Brice, Pauline Radford, John and Ribrag, Vincent Molin, Daniel Vassilakopoulos, Theodoros P. and Tomita, Akihiro von Tresckow, Bastian Shipp, Margaret A. and Zhang, Yinghua Ricart, Alejandro D. Balakumaran, Arun and Moskowitz, Craig H. KEYNOTE-087 Investigators

Abstract

Purpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2. Pembrolizumab, a programmed death 1-blocking antibody, demonstrated a high overall response rate (ORR) in patients with relapsed or refractory classic Hodgkin lymphoma (rrHL) in phase I testing. Methods KEYNOTE-087 (ClinicalTrials.gov identifier, NCT02453594) was a single-arm phase II study of pembrolizumab in three cohorts of patients with rrHL, defined on the basis of lymphoma progression after (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV); (2) salvage chemotherapy and BV, and thus, ineligible for ASCT because of chemoresistant disease; and (3) ASCT, but without BV after transplantation. Patients received pembrolizumab 200 mg once every 3 weeks. Response was assessed every 12 weeks. The primary end points were ORR by central review and safety. Results A total of 210 patients were enrolled and treated (69 in cohort 1, 81 in cohort 2, and 60 in cohort 3). At the time of analysis, patients received a median of 13 treatment cycles. Per central review, the ORR was 69.0% (95% CI, 62.3% to 75.2%), and the complete response rate was 22.4% (95% CI, 16.9% to 28.6%). By cohort, ORRs were 73.9% for cohort 1, 64.2% for cohort 2, and 70.0% for cohort 3. Thirty-one patients had a response >= 6 months. The safety profile was largely consistent with previous pembrolizumab studies. Conclusion Pembrolizumab was associated with high response rates and an acceptable safety profile in patients with rrHL, offering a new treatment paradigm for this disease. (C) 2017 by American Society of Clinical Oncology

Published
2017

148. Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers

Author

Rossi, Cédric, primary, Gilhodes, Julia, additional, Maerevoet, Marie, additional, Herbaux, Charles, additional, Morschhauser, Franck, additional, Brice, Pauline, additional, Garciaz, Sylvain, additional, Borel, Cécile, additional, Ysebaert, Loïc, additional, Obéric, Lucie, additional, Lazarovici, Julien, additional, Deau, Bénédicte, additional, Dupuis, Jehan, additional, Chauchet, Adrien, additional, Abraham, Julie, additional, Bijou, Fontanet, additional, Stamatoullas‐Bastard, Aspasia, additional, Malfuson, Jean‐Valère, additional, Golfier, Camille, additional, Laurent, Camille, additional, Pericart, Sarah, additional, Traverse‐Glehen, Alexandra, additional, Kanoun, Salim, additional, Filleron, Thomas, additional, Casasnovas, René‐Olivier, additional, and Ghesquières, Hervé, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results